Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 9/1/2025

Indications for Treating Subclinical Hypothyroidism

Definite Indications for Treatment

  • Patients with subclinical hypothyroidism and TSH levels consistently above 10 mIU/L should receive levothyroxine therapy due to higher risk of progression to overt hypothyroidism (5% per year) 1, 2
  • All pregnant women with subclinical hypothyroidism should be treated regardless of TSH level to reduce risks of pregnancy complications and potential adverse effects on fetal neurocognitive development 4

Consider Treatment in TSH 4.5-10 mIU/L with:

  • Symptomatic patients with symptoms compatible with hypothyroidism may benefit from a trial of levothyroxine, though improvement should be carefully evaluated to distinguish from placebo effect 1, 3, 5
  • Patients with positive TPO antibodies, indicating autoimmune etiology and higher risk of progression to overt hypothyroidism (4.3% vs 2.6% per year in antibody-negative individuals) 1, 3

Monitoring Without Treatment (TSH 4.5-10 mIU/L)

  • For patients with TSH between 4.5-10 mIU/L without risk factors, monitoring with thyroid function tests at 6-12 month intervals is recommended 1, 2, 3

Evaluation Before Treatment

  • Confirm diagnosis with repeat TSH and FT4 measurement after 2 weeks to 3 months 3, 5
  • Evaluate for signs/symptoms of hypothyroidism, previous thyroid treatment, thyroid enlargement, and family history of thyroid disease 1, 3
  • Review lipid profiles as subclinical hypothyroidism may affect cholesterol levels 1, 3

Treatment Considerations

  • Potential risks of therapy include development of subclinical hyperthyroidism (occurs in 14-21% of treated patients) 1, 2, 4